Apolipoprotein E e4 allele frequency in patients with multiple system atrophy

doi:10.1016/S0304-3940(96)13316-4

Neuroscience Letters

Volume 221, Issues 2–3, 17 January 1997, Pages 161-164

https://doi.org/10.1016/S0304-3940(96)13316-4 Get rights and content

Abstract

The glial cytoplasmic inclusion provides a histological hallmark for multiple system atrophy, a group of neurodegenerative disorders including: striatonigral degeneration, olivopontocerebellar atrophy, and Shy-Drager syndrome. Apolipoprotein E (APOE) genotype was determined by the polymerase chain reaction and restriction digestion of DNA extracted from frozen brain tissue from 22 patients (64.9±2.2 years) with clinically and neuropathologically verified multiple system atrophy (MSA). In addition, brain tissue from 36 age- and sex-matched patients who died with Alzheimer's disease (68.8±1.6 years) and 66 neurologically and psychiatrically normal subjects (66.6±1.8 years) was genotyped. The APOE e4 allele frequency in the Alzheimer's disease subjects was significantly increased (0.44, P<0.001), as has been reported previously. The APOE e4 allele frequency of the MSA cases (0.11) was not significantly different from that of the control subjects (0.12). These data indicate that the APOE e4 allele is not a risk factor for multiple system atrophy.

Section snippets

Acknowledgements

We would like to thank Mrs. Linda Elliott and Mr. Paul Carter for technical help with the preparation of the tissue and Mrs. Sandra Randell for secretarial assistance. This work was supported by the Medical Research Council, the Royal Society (N.J.C.), and the Parkinson"s Disease Society of the United Kingdom.

References (30)

P. Amouyel et al.
The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease
Lancet
(1994)
H. Arai et al.
Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease
Lancet
(1994)
D. Avramopoulos et al.
Apolipoprotein E allele distribution in parents of Down's syndrome children
Lancet
(1996)
M.I. Papp et al.
Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome)
J. Neurol. Sci.
(1989)
M.I. Papp et al.
Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy
J. Neurol. Sci.
(1992)
S.M. Pickering-Brown et al.
Apolipoprotein E allelic frequencies in patients with lobar atrophy
Neurosci. Lett.
(1995)
S.E. Poduslo et al.
Apolipoprotein E and B alleles in Parkinson's patients
Neurosci. Lett.
(1995)
D. St Clair et al.
Apolipoprotein E e4 allele frequency in patients with Lewy body dementia
Alzheimer's disease and age-matched controls, Neurosci. Lett.
(1994)
M. Salvatore et al.
Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease
Neurosci. Lett.
(1995)
W.J. Strittmatter et al.
Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype
Exp. Neurol.
(1994)

P.R. Wenham et al.

Apolipoprotein E genotyping by one-stage PCR

Lancet

(1991)

T. Wisniewski et al.

Apolipoprotein E: binding to soluble Alzheimer's β-amyloid

Biochem. Biophys. Res. Commun.

(1993)

American College of Medical Genetics, Statement on use of apolipoprotein E testing for Alzheimer's disease, J. Am. Med....

E.H. Corder et al.

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Science

(1993)

E.H. Corder et al.

Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer's disease

Nature Genet.

(1994)

Cited by (34)

A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward
2019, Neuron
Citation Excerpt :
Despite this strong link to DLB, APOE has not clearly been associated with other synucleinopathies such as multiple system atrophy (MSA) or Parkinson’s disease (PD). MSA is relatively rare, and to date studies examining a link between APOE and disease risk or age at onset have been negative (Cairns et al., 1997; Morris et al., 2000, 2001). In PD, an earlier meta-analysis suggested that APOE2 may be associated with increased risk (Huang et al., 2004a), but subsequent work further updated this meta-analysis and suggested that no clear significant associations could be determined (Williams-Gray et al., 2009).
Alzheimer’s disease (AD) is considered a polygenic disorder. This view is clouded, however, by lingering uncertainty over how to treat the quasi “monogenic” role of apolipoprotein E (APOE). The APOE4 allele is not only the strongest genetic risk factor for AD, it also affects risk for cardiovascular disease, stroke, and other neurodegenerative disorders. This review, based mostly on data from human studies, ranges across a variety of APOE-related pathologies, touching on evolutionary genetics and risk mitigation by ethnicity and sex. The authors also address one of the most fundamental question pertaining to APOE4 and AD: does APOE4 increase AD risk via a loss or gain of function? The answer will be of the utmost importance in guiding future research in AD.
The Importance of Olfactory and Motor Endpoints for Zebrafish Models of Neurodegenerative Disease
2017, Animal Models for the Study of Human Disease: Second Edition
Olfactory dysfunction may be caused by many factors, including physical damage and genetic abnormalities, but is also an accessible early stage symptom of several neurodegenerative diseases. Not only is the olfactory system subject to the specific histological abnormalities, but patients also lose the capacities to detect, identify, and discriminate between odors. In addition to olfactory deficits, motor dysfunction is another prominent manifestation of these conditions. Various approaches have engineered zebrafish (Danio rerio) models for neurodegenerative diseases. Despite encouraging results, there remains a great deal of potential in testing the models using established methods of olfactory and motion assessment. This chapter discusses current zebrafish models and suggests olfactory and motor endpoints for Parkinson’s, Alzheimer’s, Huntington’s disease, multiple system atrophy, and amyotrophic lateral sclerosis.
The Importance of Olfactory and Motor Endpoints for Zebrafish Models of Neurodegenerative Disease
2013, Animal Models for the Study of Human Disease
Olfactory dysfunction, although caused by many factors including physical damage and genetic abnormalities, is an early stage symptom of several neurodegenerative diseases. Not only is the olfactory system subject to the specific histological abnormalities but patients also lose the capacities to detect, identify, and discriminate among odors. In addition to olfactory deficits, motor dysfunction is another prominent manifestation of these conditions. Recent studies have begun to create zebrafish (Danio rerio) models for neurodegenerative diseases. Despite successful execution, there remains a great deal of potential in testing the models using established methods of olfactory and motion assessment. This chapter discusses the current zebrafish models and suggests olfactory and motor endpoints for Parkinson's, Alzheimer's, Huntington's, multiple system atrophy, and amyotrophic lateral sclerosis.
Genetic players in multiple system atrophy: Unfolding the nature of the beast
2011, Neurobiology of Aging
Citation Excerpt :
This is so far the only report on a MSA patient with abnormalities in the ZNF9 gene. Likewise, apolipoprotein E (APOE), associated with Alzheimer's disease (AD) and DLB, is not considered to be a player in MSA pathogenesis and does not contribute to an earlier disease onset (Cairns et al., 1997; Morris et al., 2000, 2001). No disease association has furthermore been detected for genetic variants of the progranulin (PRGN) gene (Yu et al., 2010).
Multiple system atrophy (MSA) is a fatal oligodendrogliopathy characterized by prominent α-synuclein inclusions resulting in a neuronal multisystem degeneration. Until recently MSA was widely conceived as a nongenetic disorder. However, during the last years a few postmortem verified Mendelian pedigrees have been reported consistent with monogenic disease in rare cases of MSA. Further, within the last 2 decades several genes have been associated with an increased risk of MSA, first and foremost the SNCA gene coding for α-synuclein. Moreover, genes involved in oxidative stress, mitochondrial dysfunction, inflammatory processes, as well as parkinsonism- and ataxia-related genes have been implicated as susceptibility factors. In this review, we discuss the emerging evidence in favor of genetic players in MSA.
Etiology, Pathology, and Pathogenesis
2010, Blue Books of Neurology
Citation Excerpt :
The reported association between alcohol dehydrogenase 1C gene stop mutation and MSA in a British population, but not in a German population, needs further substantiation.28 The apolipoprotein E e4 allele frequency of MSA cases was not significantly different from that of control subjects.29 Similarly, others have reported no effect of apolipoprotein E tau, α-synuclein, or synphilin gene variability on the development of MSA.21,30
This chapter reviews the available evidence on the etiopathogenesis and pathology of multiple system atrophy (MSA). MSA is a neurodegenerative disease of unknown etiology that manifests clinically with autonomic failure, parkinsonism, cerebellar ataxia, and pyramidal signs in various combinations. The finding of polymorphisms in various proinflammatory pathways is a promising step in elucidating the pathogenesis of MSA. There is significant overlap in the clinical features between the fragile X–associated tremor/ataxia syndrome (FXTAS) and atypical parkinsonism—in particular, MSA associated with cerebellar ataxia (MSA-C). Polymorphisms associated with an elevated risk for MSA include interleukin (IL)-1A, IL-1β, IL-8, intercellular adhesion molecule-1, tumor necrosis factor-1031C,38, and α₁-antichymotrypsin. Diffuse neuronal cytoplasmic α-synuclein immunoreactivity is often referred to as “preinclusions” and may reflect incipient inclusion or Lewy body-like formation enhanced in sympathetic ganglia in MSA patients. Although MSA is now widely accepted as a single multisystem disease, there is evidence of clinicopathological heterogeneity. Autonomic failure in MSA is caused by dysfunction of (1) central and preganglionic efferent autonomic activity, (2) neuronal networks in the brainstem that control cardiovascular and respiratory function, and (3) the neuroendocrine component of the autonomic regulation via the hypothalamopituitary axis. The correlation of subregional glial cytoplasmic inclusion (GCI) density and neuronal loss suggests that α-synuclein aggregation is tightly linked to selective neurodegeneration in MSA.
Chapter 3 Multiple System Atrophy
2007, Blue Books of Neurology
This chapter discusses the concept of multiple system atrophy. Multiple system atrophy (MSA) comprises three manifestations described as olivopontocerebellar atrophy (OPCA), Shy–Drager syndrome (SDS), and striatonigral degeneration (SND). Cerebellar ataxia, Parkinsonism with short-lasting response to levodopa, and autonomic failure with incontinence and orthostatic dysfunction are clinical hallmarks of the disease, whereas dementia, pill-rolling tremor, gaze palsy, and marked neuropathy are uncommon in MSA. Magnetic resonance imaging (MRI), (123I)-metaiodobenzylguanidine (MIBG), and singlephoton emission computed tomography (SPECT) are useful tools in the differentiation of MSA to Parkinson's disease (PD) and idiopathic cerebellar ataxia. Oligodendroglial cytoplasmic inclusions (GCIs) containing ubiquitin, tau, and α-synuclein constitute the pathologic hallmark in all three clinical subtypes of MSA. Because of the abundant presentation of α-synuclein in GCIs, MSA is regarded as a synucleinopathy. The overexpression of α-synuclein in genetically modified mice in combination with 3-nitropropionic acid toxicity replicated strikingly human neuropathology. These mouse models provide new tools to disclose the basic pathophysiologic mechanisms of MSA. At present, pharmacotherapy is restricted to the symptomatic treatment of Parkinsonism, autonomic failure, sleep disturbance, and depression. Physiotherapy, speech therapy, and occupational therapy help to maintain mobility as long as possible and improve functional ability in daily living.

View all citing articles on Scopus

View full text

Apolipoprotein E e4 allele frequency in patients with multiple system atrophy

Abstract

Section snippets

Acknowledgements

Lancet

Lancet

Lancet

J. Neurol. Sci.

J. Neurol. Sci.

Neurosci. Lett.

Neurosci. Lett.

Alzheimer's disease and age-matched controls, Neurosci. Lett.

Neurosci. Lett.

Exp. Neurol.

Lancet

Biochem. Biophys. Res. Commun.

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Science

Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer's disease

Nature Genet.